I think it's going to close well based on the sales numbers. Only worry is a BABA top signal. Markets reversed hard after the stock opened.
Excellent numbers, ads finally starting to increase awareness. Once the Bel-Phen news/awareness increases we could see much larger increases, a repeat of history without the side effects. Who the heck is selling/shorting here?
after a H&S top let's see if there's anything to this rumor. Maybe Monday or after the close or maybe another false start. Stock is too cheap either way, it's a buy IMO.
where did you see this? If so, good for them (finally) and they need to keep on going. There are too many VP/SVP hanger's on that are doing nothing to enhance shareholder value. Maybe Bus Dev will be next. I can think of a few more ppl I would replace for sure...
see the new 8k posted on the Nasdaq site. These people have no shame and no clue about their responsibility to the shareholders. CEO, IR, Bus Dev, most of the BOD are dead wood and need to be replaced. IMO of course.
They need to do something to unlock the value and provide a return to the shareholders. I am sure they are all feeling the heat given the terrible relative performance YTD. If I were the responsible person at Vanguard, I would be on the phone weekly to find out WTH they are doing to turn things around.
should be up no? Maybe we will get some news from Roche, another partner, or the IV board soon.
What has happened in 3 months to drop the stock price by 33%? Industry is up, scripts are up, some new competitors, but not unexpected, Bel-Phen looks more likely, getting closer to smoking results. Jack is unfortunately still the CEO, that's the only negative I see.
Ignore the short hedge fund lies and buy/hold IMO. ARNA should be worth $6-8 within the next 12 months. I am going to hold and watch now, no time to read short lies or SV pumping.
if/when they do, ACAD will/would have a much higher market cap. It's not yet/far from a done deal. I am a bit skeptical about the thought that a tiny biotech will successfully supply 100,000+ patients. Seems like a tall task and the reason a large pharma should buy them at a reasonable price.
I think it's time to load up, just IMO. I get the feeling something is happening. Why have they not hired an IR person? I could have found then 3-4 good people in 1-2 months. It might be that no self respecting IR person wants to work for Jack, or...the company is considering options for which they would not need an IR pro. Bottom line, stock is cheap, problems are fixable, 1) get rid of Jack 2) get rid of Jack 3) insiders/directors buy some stock 4) find some new institutional buyers 5) do some deals 6) do some deals that lower the burn rate or 7) just sell to the highest bidder.